Regulatory interleukin-10 (IL-10)-producing B cells (B10 cells) play a critical role in preventing and curing autoimmune diseases in experimental mouse models. However, the precise cellular and molecular mechanisms of action of B10 cells in humans, especially in patients with Crohn's disease (CD), remain to be determined. miR-155 regulates many physiological and pathological conditions, including inflammation such as that in CD. In this study, we aimed to explore the effect of miRNA-155 on IL-10 production by B cells in healthy controls (HCs) and CD patients. Interestingly, we found that CD24 hi CD27
CD25
− T cells, as well as TNFα production by monocytes. Our study demonstrates the critical role of miRNA-155 in the regulation of IL-10 production by B cells and reveals the novel molecular mechanism underlying the functional impairment of B10 cells in CD patients. Our study has the potential to drive the development of B10 cell-based strategies to ameliorate disease progression in CD patients. it has been reported in mice that B10 cells are enriched in B cells that express CD1d and CD5, while in humans, B10 cells are enriched in B cells that express CD24, CD27, and CD38 (8) (9) (10) . Toll-like receptor (TLR) agonists, such as CpG oligonucleotides, potently induce B cells to produce IL-10 by activating STAT3 phosphorylation in human B cells (11) . A proliferation-inducing ligands also promote the production and regulatory functions of IL-10 in human B cells (12) . Additionally, IL-35 induces regulatory B cells to suppress autoimmune diseases (13) . However, the signaling pathways responsible for the development and function of B10 cells in humans are largely unknown; in particular, the roles of microRNAs (miRNAs) and chromatin regulators in these processes have not yet been demonstrated. Crohn's disease (CD), characterized by inappropriate and exacerbated immune responses within the gastrointestinal tract, is the most common form of inflammatory bowel disease (IBD). The pathogenesis of CD has been associated with complex interactions among the host's genetic susceptibility, environmental factors, and immune cell imbalance, but most of the molecular mechanisms remain unknown (14) (15) (16) . Recent studies have found that mutations in genes encoding IL-10 and IL-10R are associated with a very early-onset form of IBD (17) . Regulatory B cells producing IL-10 have been shown to play an important role in maintaining intestinal homeostasis, and a lack of B10 cell-mediated suppression has been associated with CD development (18) . Sattler et al. reported that B10 cells effectively attenuate mucosal inflammatory responses in the gut (19) , and CD patients are characterized by a decrease in regulatory B cells (20, 21) . However, the mechanisms underlying the reduction in the number and function of B10 cells in CD patients have not been fully investigated.
MicroRNAs can post-transcriptionally modulate the expression of multiple target genes and play a critical role in the development of inflammatory diseases (22, 23) . It has been reported that miR-155 is a typical multifunctional miRNA involved in hematopoiesis, inflammation and immune responses and whose expression is induced by inflammatory cytokines and TLR ligands (24, 25) . Recently, the impact of miRNA-155 on the colonic mucosa of patients with ulcerative colitis (UC) was studied, and it was revealed that miR-155 modulates the inflammatory phenotype of intestinal myofibroblasts by targeting SOCS1; miR-155 has also been shown to be involved in the pathogenesis of UC by targeting FOXO3a (26, 27) . Thelma et al. reported that miR-155 activates cytokine expression in Th17 cells (28) . However, until now, no study has reported the relationship between miR-155 and B10 cells, especially in patients with CD. Thus, the role of miR-155 in modulating the development and function of B10 cells warrants further study. Therefore, the purpose of the current study was to count and characterize B10 cells in healthy subjects and CD patients. Additionally, we wanted to explore the effect of miRNA-155 in modulating the development and function of B10 cells. Our study reveals the critical role of miR-155 in the regulation of IL-10 production in B cells and demonstrates novel molecular mechanisms underlying the impaired number and function of B10 cells in CD patients, which will promote the development of B10 cell-based strategies to prevent disease progression in CD patients.
MaTerials anD MeThODs

Patients
We examined B10 cells in the peripheral blood of patients with active CD (N = 30; 16 men; 14 women; mean age: 32.5 ± 3.0 years; range: 14-52 years). Samples from healthy individuals (N = 50; 25 men; 25 women; mean age: 32.1 ± 2.5 years; range: 18-56 years) served as controls. Active CD was prospectively defined as a Crohn's disease activity index (CDAI) >150. All the patients provided written informed consent to participate in the study, which was carried out in accordance with the principles of the Declaration of Helsinki and was approved by the ethics committee of Xinhua Hospital.
Flow cytometric analysis
For intracellular cytokine staining, cells were stimulated with a cell stimulation cocktail plus protein transport inhibitors (eBioscience) for 5 h. Then, the cells were fixed and permeabilized with Cytofix/Cytoperm buffer, and intracellular cytokines were stained with antibodies against IL-10, IFNγ, and TNFα (eBioscience). Flow cytometric analysis was performed with a FACS Canto II instrument (BD Bioscience) and FlowJo software (TreeStar).
cytokine Production Measurements
Interleukin-10 and TNFα levels were measured with ELISA kits according to the manufacturer's instructions (R&D Systems).
immunoblot analysis
Cells were directly lysed and subjected to 10% SDS-PAGE. Immunoblotting was performed after transferring the proteins onto nitrocellulose membranes (Schleicher & Schuell Microscience) with a Mini Trans-Blot apparatus (Bio-Rad). After 2 h of blocking, the membranes were incubated overnight at 4°C with the following specific primary antibodies: anti-Jarid2 (Abcam), anti-p-STAT3, anti-STAT3 (Cell Signaling), and anti-β-actin Abs (Sigma-Aldrich). After the membranes were washed, subsequent incubations with the appropriate HRP-conjugated secondary antibodies were conducted for 1 h at room temperature; after extensive washing, the signals were visualized with an ECL substrate (Pierce Chemical).
real-time Pcr
Expression levels of miR-155, IL-10, TNFα, and Jarid2 were measured by quantitative RT-PCR (qRT-PCR) using a SYBR green-based real-time quantitative PCR assay (Qiagen). The data were collected and quantitatively analyzed using an ABI Prism 7900 Sequence Detection System (Applied Biosystems). The relative level of miR-155 was normalized to that of small nuclear RNA U6, which is a ubiquitously expressed small nuclear RNA that has been widely used as an internal control. Primers for miR-155 and the small nuclear RNA U6 were obtained from Invitrogen. The sequences of the primers are as follows: miR-155, forward 5′-TTA ATG CTA ATC GTG ATA GGG G-3′ and reverse 5′-CGA ATT CTA GAG CTC GAG GCA GG-3′; U6, forward 5′-CTC GCT TCG GCA CA-3′ and reverse 5′-CGA ATT CTA GAG CTC GAG GCA GG-3′; IL-10, forward 5′-CTT CGA GAT CTC CGA GAT GCC TTC-3′ and reverse 5′-ATT CTT CAC CTG CTC CAC GGC CTT-3′; Jarid2, forward 5′-GCT TCC CAC CAG GAT GAC AG-3′ and reverse 5′-CCA AGG AGC CCA TTC ACA GT-3′; TNFα, forward 5′-CAC CAC TTC GAA ACC TGG GA-3′ and reverse 5′-AGG AAG GCC TAA GGT CCA CT-3′; and GAPDH, forward 5′-GCC ACC CAG AAG ACT GTG GAT GGC-3′ and reverse 5′-CAT GTA GGC CAT GAG GTC CA C CAC-3′. The data are presented according to the following equations: target miRNA expression = 2ΔCt, with ΔCt = (U6 Ct-target miRNA Ct), or target mRNA expression = 2ΔCt, with ΔCt = (GAPDH Ct-target mRNA Ct).
cFse labeling
We added CFSE (Sigma-Aldrich) to B cell suspensions at a final concentration of 2 µM for 8 min at 37°C; then, we washed the cells three times with PBS and resuspended them in complete RPMI medium.
In Vitro coculture assay 
mirna Mimic or inhibitor Transfection
Isolated B cells (3 × 10 6 B cells, Miltenyi Biotec) in 100 µL of Amaxa mix were electroporated with 300 nM miR-155 mimic or inhibitor or control (Sigma) according to the manufacturer's instructions. Six hours after transfection, we added 100 nM CpG oligonucleotides to the culture. Then, we harvested the cells for further analysis.
sirna Knockdown
We performed RNA interference experiments using electroporation (Amaxa) according to the manufacturer's protocol. Briefly, we mixed 300 nM Jarid2-specific siRNA or control siRNA (Sigma) with 3 × 10 6 B cells in 100 µL of Amaxa mix and transfected the cells via electroporation according to the manufacturer's instructions. Six hours after transfection, we added 100 nM CpG oligonucleotides to the culture. Then, we harvested the cells for further analysis.
isolation of cytokine-Producing B cells
We followed a previously described protocol to isolate cytokineproducing B cells (10, 29) . First, B cells were pre-enriched via depletion of non-B cells (Miltenyi Biotec) and cultured for 2 days under stimulation with 100 nM CpG oligonucleotides. Second, stimulation cocktail (eBioscience) was added to the cultures for 3 h to induce IL-10 secretion. Third, the viable cytokineproducing B cells were specifically isolated using a cytokine secretion assay according to the manufacturer's instructions. Briefly, the pre-enriched B cells were incubated with IL-10 and TNFα catch reagents. The cells were subsequently labeled with IL-10 detection antibody or TNFα detection antibody conjugated to PE or APC, respectively. The IL-10-and TNFα-secreting cells were then sorted by FACS (BD Aria II). The purity of the cells was further confirmed by measuring the expression of IL-10 and TNFα by q-RT-PCR.
chiP
ChIP assays were performed using a ChIP assay kit (Millipore) with modifications. Isolated B cells (5 × 10 6 cells) were fixed in 1% formaldehyde, and the chromatin was sonicated and pre-cleared by incubation with Protein A/G agarose/salmon sperm DNA (Millipore). The precleared chromatin was immunoprecipitated with antibodies against H3K27me3 (Abcam) overnight at 4°C or mouse IgG monoclonal antibody followed by incubation with Protein A/G agarose/salmon sperm DNA for 1 h. The immunoprecipitates were denatured, and the DNA was purified. The amount of immunoprecipitated DNA was quantified by real-time PCR using SYBR Green and the ABI PRISM 7500 Sequence Detection System (Applied Biosystems). The primers used for the PCR analysis of the IL-10 promoter locus are as follows: forward: 5′ to 3′, CCA GGT AGA GCA ACA CTC; reverse: 5′ to 3′ CAG GCT CCT TTA CCC CGA TT.
statistics
We used one-way analysis of variance to initially determine whether an overall statistically significant difference existed before using Tukey's post hoc test and the two-tailed paired or unpaired Student's t-test to analyze the differences between two groups. The results are presented as the means ± SEM. A value of P < 0.05 was considered statistically significant. 
B cells
First, we used two markers, CD24 and CD27, to determine levels of IL-10 production in different B cell subsets (10) . The gating strategies and isotype control are shown in Figure  S1 in Supplementary Material. As reported by other studies, we found that the CD24 hi CD27 + B cell subset produced higher levels of IL-10 after stimulation with CpG oligonucleotides for 48 h compared to those produced by other B cell subsets ( Figure 1A) . In addition, these data were supported by the TLR9 expression measured in different B cells subsets ( Figure 1B) ; the data show that the CD24 hi CD27
+ B cells, which are more sensitive to stimulation by CpG oligonucleotides, expressed higher levels of TLR9 than other B cell subsets. Isolated human CD19
+ B cells and were stimulated with CPG or not for 48 h, the miRNA profiles of the cells were examined, and we found that miR-155 was significantly increased after CPG stimulation ( Figure S2 in Supplementary Material). Next, we isolated different B cell subsets according to the CD24 and CD27 markers and analyzed the expression of IL-10 and miR-155 using Q-PCR. We observed that the expression of miR-155 and IL-10 increased over time with the stimulation of CD24 hi CD27
+ B cells by CpG oligonucleotides in culture; the expression reached its highest level at 24 h before mir-155 increases the expression of the il-10 gene in B cells by regulating the Dna-Binding Protein Jarid2
Next, we explored the effect of miR-155 on the regulation of IL-10 production. We isolated CD19 + B cells from healthy controls (HCs) and overexpressed miR-155 mimic or control using electroporation and stimulated the cells with CpG oligonucleotides for an additional 48 h. The survival of B cells was not significantly changed after transfection with the miR-155 mimic or control ( Figure S2A in Supplementary Material). We found that the miR-155 expression level was significantly increased in the mimic-transfected group compared to that in the control group (18.33 ± 2.23 and 5.18 ± 0.77%, respectively), as well as the IL-10 production level (Figures 2A-C) . As STAT3 phosphorylation is important for IL-10 production (11), we measured the phosphorylation of STAT3 in B cells overexpressing miR-155. By Western blot, we observed that after overexpression of miR-155 mimic in B cells, STAT3 phosphorylation and IL-10 expression were significantly increased ( Figure 2D ). We also conducted functional assays and found that when B cells had overexpression of miR-155 and were cocultured with purified CD4 + T cells, INFγ production by T cells was significantly reduced (Figure 2E) . In contrast, when we sorted CD24 hi CD27
+ B cells from the HCs and electroporated them with miR-155 inhibitor, the survival of B cells was not significantly changed after transfection with the miR-155 inhibitor or control ( Figure S2B in Supplementary Material). We found that the expression level of miR-155 was decreased (14.11 ± 1.050 and 2.318 ± 0.6336%, respectively) and that the production level of IL-10 was significantly reduced compared to the corresponding levels in the control group (Figures 2F-H) . Also, the inhibition of INFγ production by T cells was significantly decreased when CD24 hi CD27 + B cells were transfected with miR-155 inhibitor ( Figure 2I ). These data demonstrate that miR-155 regulates IL-10 production in B cells, as well as B cell function.
Furthermore, we wanted to explore the molecular mechanisms by which miR-155 regulates IL-10 expression in B cells. It has been reported that DNA-binding protein Jarid2 recruits polycomb repressive complex 2 (PRC2) to chromatin and inhibits gene expression in miR-155-deficient cells (28) ; however, this molecular mechanism has not been examined in B cells. Therefore, we speculated that miR-155 can activate IL-10 production by regulating Jarid2 and relieving the H3K27 histone methylation repression of IL-10. First, we sorted the B cell subsets according to their expression of CD24 and CD27 using FACS and then measured Jarid2 gene expression by Q-PCR; we found that CD24 hi CD27
+ B cells express much lower levels of Jarid2 than other B cell subsets ( Figure 3A) . We also analyzed Jarid2 expression in CD24 hi CD27
+ B cells in response to stimulation with CpG oligonucleotides over a time course and found that Jarid2 expression decreased with increasing stimulation time ( Figure 3B ). In addition, Jarid2 expression was negatively correlated with IL-10 gene expression in the CD24 hi CD27
+ B cells ( Figure 3C) . Furthermore, when the CD24 hi CD27
+ B cells were electroporated with miR-155 inhibitor, Jarid2 gene and protein levels were significantly increased compared to those in the control group (Figures 3D,E) . These data indicate that miR-155 can modulate Jarid2 expression. We further sorted the IL-10 + and IL-10 − B cells using beads combined with FACS as previously described (29) . We found that the IL-10 + B cells expressed much lower levels of Jarid2 than the IL-10 − B cells ( Figure 3F ). When Jarid2 expression was knocked down in the B cells and the cells were stimulated with CpG oligonucleotides for 48 h, the B cells produced much higher levels of IL-10 and TNFα than the control group (Figures 3G-I) . It has been reported that Jarid2 can silence the transcription of its target genes through H3K27me3 (28) . Therefore, we used ChIPqPCR to determine whether Jarid2 directly targets H3K27me3 and regulates IL-10 production in B10 cells. As the data showed when the B cells were electroporated with Jarid2-specific siRNA and H3K27me3 was pulled down, the binding of H3K27me3 to the promoter of IL10 was significantly reduced compared to that in the control group (Figure 3J ). These data demonstrate that miR-155 activates IL-10 gene expression in B cells by regulating the Jarid2 target H3K27me3 and mediating repression.
The number of cD19
cells Was Decreased, and Their Function Was impaired in cD Patients
We then determined the number of B10 cells in CD patients. Interestingly, there was no significant difference in IL-10 production and Jarid2 mRNA expression in the B cells from the HC and CD groups ( Figure 4A and Figure S3 in Supplementary Material). Next, we determined the percentages of B cell subsets using the markers CD24 and CD27 and found that the number of CD24 hi CD27
+ B cells were markedly reduced in the CD patients (12.43 ± 0.758 and 5.49 ± 0.912%, respectively) ( Figure 4B) . Additionally, the CD24 hi CD27 + B cells from CD patients produce lower levels of IL-10 than those from the HCs (Figure 4C) + B cells from the CD patients could not (Figure 4D) . Additionally, when activated B cells were cocultured with purified CD4 + T cells, IFNγ production by the T cells was significantly reduced by the B cells from HCs but not by those from the CD patients ( Figure 4E) 
CD27
+ B cells in CD patients. It has been reported that B cells can produce the inflammatory cytokine IL-6 and contribute to the pathogenesis of multiple sclerosis (30) . In our study, we did not find an increase in IL-6 level in the B cells of CD patients (data not shown); however, interestingly, we found 
CD25
− T cells isolated from HCs for 48 h. IFNγ expression in the CD4 T cells was analyzed by FACS. The data shown are the mean ± SEM. The asterisks represent statistical significance between the groups. *P < 0.05; **P < 0.01. (Figures 5A-D) . We then sorted the
IL-10
+ /TNFα + and IL-10 + /TNFα − B cells using beads combined with FACS and determined their function. As shown by the data, the expression level of IL-10 mRNA was very high in both subsets, but that of TNFα mRNA was very low in the IL-10 + /TNFα − B cells ( Figure 5E ). Furthermore, we determined the proliferative Figure 5F ). In addition, when the isolated subsets were cocultured with purified CD4 + CD25 − T cells and stimulated with anti-CD3 for 3 days, the Foxp3 and IFNγ expression levels were analyzed, and the IL-10 + /TNFα − B cells demonstrated a greater ability to induce Foxp3 expression and a greater ability to inhibit IFNγ production by the CD4 +
CD25
− T cells (Figures 5G,H) . Also, IL-10 + /TNFα − B cells could inhibit monocyte production of TNFα better than other B cell subsets ( Figure 5I ). These data suggest that higher numbers of IL-10 + monocytes isolated from HCs were cultured for 24 h and then stimulated with 100 µg/mL LPS before the cytoplasmic TNFα expression was assessed. The data are shown as the mean ± SEM (N = 3). *P < 0.05, **P < 0.01. (Figures 6B-E) . When the CD19
+ B cells were transfected with the miR-155 inhibitor, the IL-10 and TNFα expression levels were decreased in both HC and CD groups. Interestingly, the ratio of IL-10
B cells to IL-10
+ /TNFα − B cells in the CD patients was still higher than that in the control group (Figures 6B-E) . Therefore, in the CD patients, miR-155 could induce B cells to simultaneously secrete both IL-10 and a much higher level of TNFα, which may have reduced the function of CD19
+ B cells.
DiscUssiOn
Abnormalities in IL-10-producing regulatory B cells contribute to the development and progression of autoimmune diseases (31 (33) . The cytokines produced by B cell subsets are associated with both pathogenic and protective roles in various immunological disorders. Therefore, in the inflammatory state, B10 cells may not always perform their protective functions.
B cells have great potential to regulate both innate and adaptive arms of the immune system by releasing cytokines. These cytokine-producing B cell subsets have multifunctional roles in health and diseases, playing pathologic as well as protective roles in autoimmunity, infection, and allergies (34) . However, which B cells produce pro-and anti-inflammatory cytokines and the plasticity of B cell function depends on the environmental signals. B cell-derived cytokines, such as IL-6, IFNγ, and IL-17, influence the development of effector and memory CD4 + T cell responses (35) . TNFα produced by B cells is necessary for the formation of lymphoid structures and the production of antigenspecific IgG1 (36) . TNFα has been directly implicated in the pathogenesis of CD and plays have a crucial role in controlling intestinal inflammation and the associated clinical symptoms of CD (37, 38) . Strategies for blocking TNFα are now commonly used as standard for CD in the clinic, and their mechanisms have been widely studied (39, 40) . Interestingly, it remains unclear whether TNFα affects the number and function of regulatory B cells. In our study, we found that miR-155 could effectively induce CD24 hi CD27 + B cells to produce IL-10 and the proinflammatory cytokine TNFα, which could have led to the loss of the suppressive and regulatory functions of B10 cells in CD patients. In addition, Timmermans et al. recently reported a reduction in IgM + memory B cells in the blood of CD patients, which implies that the IgM response is impaired in the spleen and germinal center. However, transitional and CD21 low B cell numbers were increased in CD patients; therefore, the increase in transitional B cells could be compensating for the loss of mature B cells due to downregulation of CD21 (41) . In addition, therapy with TNFα blockers restored the IgM memory B-cell generation and normalized transitional B-cell levels (41). Bankó et al. also reported that the increasing number of regulatory B10 cells might contribute to the therapeutic efficacy of anti-TNF agents in rheumatoid arthritis (42) . Therefore, in future studies, we would like to determine whether the number and function of CD24 hi CD27 + B cells can be recovered when CD patients are given infliximab therapy.
Many studies have focused on the role of miR-155 in the development of inflammatory diseases (43, 44) , but the impact of miR-155 on B10 cells and CD has not been well studied. An important aspect of our study was to determine the effect that miR-155 exerts on the differentiation and function of B10 cells and further explored the molecular mechanism in HCs and CD patients. We found that miR-155 expression is correlated with IL-10 production in CD24 hi CD27 + B cells. An increase in the expression of miR-155 induces IL-10 production, while a reduction in miR-155 expression inhibits IL-10 production in B cells. Our time course analysis showed that upon stimulation with CpG oligonucleotides, the expression of miR-155 and IL-10 increased, while that of Jarid2 decreased over time, with the highest expression levels of miR-155 and IL-10 occurring after 24 h, which supports the notion that miR-155 is critical for the production of IL-10 in CD24 hi CD27 + B cells. It has been reported that TNFα production in response to anti-IgM antibody was decreased in miR-155-deficient mice (45) . In addition, our data showed that miR-155 could induce TNFα production both in the HCs and CD patients, and inhibition of miR-155 could reduce both TNFα and IL-10 production; however, the ratio of TNFα + IL-10 + /TNFα − IL-10 + B cells was still much higher in the CD patients. These data suggest that miR-155 may cause a differential effect on cytokine production that induces the higher TNFα production that contributes to disease development in CD patients.
Taken together, our study reveals a novel molecular mechanism for the regulation of IL-10-producing B cells that is mediated by the direct inhibition of Jarid2 by miR-155 and the associated decrease in H3K27me3 binding to the IL10 promoter to promote IL-10 expression. Additionally, we demonstrated that the function of CD24 hi CD27 + B cells was impaired in CD patients, likely due to the miR-155-induced production of TNFα by CD24 hi CD27 + B cells, resulting in an increase in the frequency of IL-10 + TNFα + B cells, which contribute to the functional impairment of CD24 hi CD27 + B cells. These results provide insight into the mechanisms by which miR-155 regulates IL-10 production in CD24 hi CD27 + B cells and encourage the development of B10 cell-based strategies to relieve the symptoms of Crohn's disease.
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